IBRX - ImmunityBio Inc
IEX Last Trade
3.96
0.160 4.040%
Share volume: 2,275,939
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.80
0.16
4.21%
Fundamental analysis
26%
Profitability
22%
Dept financing
25%
Liquidity
49%
Performance
25%
Performance
5 Days
-7.06%
1 Month
-25.19%
3 Months
-40.24%
6 Months
-13.19%
1 Year
139.39%
2 Year
2.86%
Key data
Stock price
$3.96
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.25 - $10.53
52 WEEK CHANGE
$1.58
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Patrick Soon-Shiong
Region: US
Website: https://www.nantkwest.com/
Employees: 535
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.nantkwest.com/
Employees: 535
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.
Recent news